SALT LAKE CITY, 26 April 2012 – BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”) announced today that the Company has introduced a new TableTop Microwave Ablation System (MicroThermX®), the T2, designed specifically for BSD’s new fee-per-use rental program. The T2 is a small, lightweight, tabletop configuration that has the same advanced features as the current MicroThermX® configuration. The Company recently launched a program that allows hospitals to purchase disposable antennas and pay a fee-per-use rental for the treatment of patients using the MicroThermX®. Portability and ease of use are key to successful implementation of the rental program. The MicroThermX® provides an interactive, intuitive, touchscreen monitor that allows the operator to easily control the treatment. The T2 configuration can be quickly and efficiently delivered to a clinical site for treatments as part of the rental program. The T2 portability will also provide our European partners an efficient and cost-effective method to market the MicroThermX® throughout Europe.
“We have expanded our sales programs for the MicroThermX® and are developing new products to ensure our success with the fee-per-use rental program,” said Harold Wolcott, BSD President and CEO. “The financial environment for capital equipment in the U.S. is changing and hospitals increasingly prefer to pay rental fees for equipment. We are encouraged by the interest in BSD’s new products and the ongoing positive clinical results from patient treatments with the MicroThermX®.”
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue and has received marketing clearance from the US FDA. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.